Amicus Therapeutics (NASDAQ:FOLD) reported quarterly sales of $88.10 million which beat the analyst consensus estimate of $86.29 million by 2.09 percent. This is a 7.23 percent increase over sales of $82.15 million the same period last year.
Earlier Health Canada Approves Pfizer Canada’s Gene Therapy In Hemophilia B
Pfizer Canada ULC announced that Health Canada approved BEQVEZ (fidanacogene elaparvovec), an adeno-associated viral (AAV) vector-based gene therapy for the treatment of adults (aged 18 years or older) with moderately
